<DOC>
	<DOCNO>NCT00087542</DOCNO>
	<brief_summary>The primary objective demonstrate investigational new drug , ACP-103 , well tolerate , worsen parkinsonism , patient Parkinson 's disease psychosis . The secondary objective determine whether ACP-103 ameliorate psychosis patient Parkinson 's disease whether ACP-103 safe Parkinson 's disease patient take multiple anti-parkinsonian medication .</brief_summary>
	<brief_title>Treatment Hallucinosis/Psychosis Parkinson 's Disease Investigational Drug</brief_title>
	<detailed_description>This Phase 2 , multi-center , randomize , placebo-controlled , double-blind trial four week ACP-103 treatment psychosis Parkinson 's disease , four week follow-up . A total 60 patient meet entrance criterion randomly assign receive placebo ( 30 patient ) active drug ( 30 patient ) . Subjects take study drug daily start Day 1 . Dose escalation occur Study Days 8 15 , patient receive stable daily dosage Day 16 Day 28 . Single step dose reduction allow period adverse event intolerance . Patients evaluate screening/baseline Study Days 1 , 8 , 15 , 28 , 57 raters blind treatment . The major response variable motoric tolerability . Secondary response variable efficacy psychosis safety . Currently , approve drug indication United States . Psychotic symptoms Parkinson 's disease patient almost always stable , often non-threatening , rarely paranoid violent content . The trial include requirement patient enrol reliable caretaker accompany patient visit reliably report patient 's daily level function . These factor argue safe inclusion four-week period placebo treatment .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Hallucinations</mesh_term>
	<criteria>Inclusion Criteria Male female patient ethnic group age eligible participation study , provide meet follow criterion : Subjects clinical diagnosis idiopathic Parkinson 's disease , define presence least three cardinal feature disease include : rest tremor , rigidity , bradykinesia and/or akinesia , postural balance abnormality , absence alternative explanation atypical feature . Psychosis , define presence visual and/or auditory hallucination , without delusion , least four week duration . Psychosis , assess item A B NPI , define Hallucinations ( Frequency x Severity ) Delusions ( Frequency x Severity ) = total score 4 great . Stable antiParkinsonian medication ( ) use least one week prior study entry . A reliable caretaker accompany subject visit , reliably report subject 's daily level function . Exclusion Criteria Patients meet following condition exclude clinical study : Inability subject caretaker provide inform consent . Pregnant breastfeeding . Female subject childbearing potential must negative urine pregnancy test screening . Female subject must nonchildbearing potential must comply doublebarrier protection method conception study least one month prior randomization one month follow completion study . Presence systemic factor contribute psychosis urinary infection , liver disease , renal failure , anemia , infection , etc . define comprehensive medical evaluation . History significant premorbid psychiatric condition diagnosis Parkinson 's disease , include major depression , mania , psychotic depression . Dementia preclude accurate assessment psychiatric assessment battery define score MMSE &lt; 21 . Use depot neuroleptic within past year . Prior exposure nondepot neuroleptic within past 90 day , except quetiapine clozapine . Quetiapine clozapinetreated patient may enrol agent discontinue due drug intolerability . Such patient must take drug within past two week . Use follow drug within past two week : benztropine , biperiden , trihexylphenidyl , amitriptyline , clomipramine , desipramine , nortriptyline , imipramine , doxepin , fluvoxamine , mirtazepine , nefazodone trazodone . Change antidepressant , anxiolytic , anticholinergic ( specifically oxybutynin , tolterodine ) , cognitive enhancer ( specifically rivastigmine , tacrine , donepezil , galantamine ) dose within past 30 day 28day duration trial . Use investigational product within past 30 day . Inability tolerate stable level antiparkinsonian medication one week . Uncontrolled angina history myocardial infarction within past three month . Concurrent illness would make use ACP103 potentially hazardous .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>Hallucinosis/Psychosis</keyword>
</DOC>